middle.news
Prescient Therapeutics Secures $9.8M to Propel PTX-100 Cancer Trial Progress
10:42am on Thursday 31st of July, 2025 AEST
•
Healthcare
Read Story
Prescient Therapeutics Secures $9.8M to Propel PTX-100 Cancer Trial Progress
10:42am on Thursday 31st of July, 2025 AEST
Key Points
Completed $3 million placement and $6.9 million share purchase plan
Total capital raise of $9.8 million to fund PTX-100 Phase 2a clinical trial
Shares issued at 4 cents, allotment expected on 8 August 2025
Funds aimed at progressing PTX-100 toward regulatory approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE